المؤلفون: van Hellemond, I.E.G., Vriens, I.J.H., Peer, P.G.M. (Petronella), Swinkels, A.C.P., Smorenburg, CH, Seynaeve, C.M. (Caroline), van der Sangen, M.J.C., Kroep, J.R. (Judith), de Graaf, H., Honkoop, AH, Erdkamp, F.L.G. (Frans ), van den Berkmortel, F.W.P., Boer, M.L. (Monique) den, de Roos, W.K., Linn, S.C. (Sabine), Imholz, A. L. T., Tjan-Heijnen, V.C.G. (Vivianne)

المصدر: International Journal of Cancer vol. 145 no. 1, pp. 274-283

مصطلحات موضوعية: breast cancer, aromatase inhibitor, chemotherapy-induced amenorrhea, chemotherapy-induced ovarian function failure (CIOFF), ovarian function recovery (OFR)

وصف الملف: application/pdf

العلاقة: http://repub.eur.nl/pub/116875Test; urn:hdl:1765/116875

الإتاحة: https://doi.org/10.1002/ijc.32093Test
http://repub.eur.nl/pub/116875Test

المؤلفون: Hellemond, I.E.G. van, Smorenburg, C.H., Peer, P.G.M., Swinkels, A.C.P., Seynaeve, C.M., Sangen, M.J.C. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F.L.G., Berkmortel, F.W.P.J. van den, Roos, W.K. de, Linn, S.C., Imholz, A.L.T., Boer, M. de, Tjan-Heijnen, V.C.G., Dutch Breast Canc Res Grp BOOG

المصدر: Breast Cancer Research and Treatment

مصطلحات موضوعية: Breast cancer, Tamoxifen, Aromatase inhibitor, Bone health, Osteoporosis, Bisphosphonates, Survival, Bone metastases, Distant recurrence-free survival

وصف الملف: application/pdf

العلاقة: https://link.springer.com/article/10.1007/s10549-020-05567-9Test; lumc-id: 111879374; https://hdl.handle.net/1887/3184752Test

الإتاحة: https://doi.org/10.1007/s10549-020-05567-9Test
https://hdl.handle.net/1887/3184752Test

المؤلفون: Hellemond, I.E.G. van, Smorenburg, C.H., Peer, P.G.M., Swinkels, A.C.P., Seynaeve, C.M., Sangen, M.J.C. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F.L.G., Berkmortel, F.W.P.J. van den, Roos, W.K. de, Linn, S.C., Imholz, A.L.T., Boer, M. de, Tjan-Heijnen, V.C.G., Dutch Breast Canc Res Grp BOOG

المساهمون: Medical Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)

المصدر: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 180(3), 675-685. Springer New York
Breast Cancer Research and Treatment, 180(3), 675-685. SPRINGER
Breast Cancer Research and Treatment, 180(3), 675-685. Springer, Cham

مصطلحات موضوعية: Cancer Research, Survival, medicine.medical_treatment, Osteoporosis, THERAPY, 0302 clinical medicine, Breast cancer, Bone Density, Bone mineral, RISK, 0303 health sciences, Bone Density Conservation Agents, Diphosphonates, Bisphosphonates, Middle Aged, CHEMOTHERAPY, Prognosis, Clinical Trial, 3. Good health, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Survival Rate, Oncology, POSTMENOPAUSAL WOMEN, 030220 oncology & carcinogenesis, ZOLEDRONIC ACID, Female, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Urology, Anastrozole, Breast Neoplasms, MECHANISMS, Bone health, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, medicine, Humans, 030304 developmental biology, business.industry, Proportional hazards model, Bone metastases, IN-VITRO, Aromatase inhibitor, Distant recurrence-free survival, Bisphosphonate, medicine.disease, Osteopenia, Bone Diseases, Metabolic, Carcinoma, Lobular, Tamoxifen, Zoledronic acid, CELLS, METASTASIS, Neoplasm Recurrence, Local, business, CLODRONATE, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f225f2bdc1f8af370c77e7235848558Test
https://hdl.handle.net/1887/3184752Test

المؤلفون: Hellemond, I.E.G. van, Vriens, I.J.H., Peer, P.G.M., Swinkels, A.C.P., Smorenburg, C.H., Seynaeve, C.M., Sangen, M.J.C. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F.L.G., Berkmortel, F.W.P. van den, Boer, M. de, Roos, W.K. de, Linn, S.C., Imholz, A.L.T., Tjan-Heijnen, V.C.G., Dutch Breast Canc Res Grp BOOG

المصدر: International Journal of Cancer

مصطلحات موضوعية: breast cancer, aromatase inhibitor, chemotherapy-induced amenorrhea, chemotherapy-induced ovarian function failure (CIOFF), ovarian function recovery (OFR)

العلاقة: lumc-id: 84255257; https://hdl.handle.net/1887/122854Test

الإتاحة: https://doi.org/10.1002/ijc.32093Test
https://hdl.handle.net/1887/122854Test

المؤلفون: Hellemond, I.E.G. van, Smorenburg, C.H., Peer, P.G.M., Swinkels, A.C.P., Seynaeve, C.M., Sangen, M.J.C. van der, Kroep, J.R., Graaf, H. de, Honkoop, A.H., Erdkamp, F.L.G., Berkmortel, F.W.P.J. van den, Boer, M. de, Roos, W.K. de, Linn, S.C., Imholz, A.L.T., Tjan-Heijnen, V.C.G., Dutch Breast Canc Res Grp BOOG

المساهمون: Medical Oncology, Otorhinolaryngology and Head and Neck Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), Interne Geneeskunde, Promovendi ODB, MUMC+: MA Medische Oncologie (9)

المصدر: International Journal of Cancer, 145(5), 1325-1333. Wiley-Liss Inc.
International Journal of Cancer
International Journal of Cancer, 145(5), 1325-1333. Wiley
International Journal of Cancer, 145(5), 1325-1333. WILEY
International Journal of Cancer, 145, 1325-1333
International Journal of Cancer, 145, 5, pp. 1325-1333

مصطلحات موضوعية: Cancer Research, medicine.medical_treatment, Osteoporosis, TERM DENOSUMAB TREATMENT, THERAPY, aromatase inhibitors, DOUBLE-BLIND, Fractures, Bone, 0302 clinical medicine, Bone Density, Medicine, Prospective Studies, Cancer Therapy and Prevention, Osteoporosis, Postmenopausal, tamoxifen, ADJUVANT LETROZOLE, Middle Aged, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Oncology, POSTMENOPAUSAL WOMEN, PREMENOPAUSAL WOMEN, 030220 oncology & carcinogenesis, ZOLEDRONIC ACID, Female, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, anastrozole, Anastrozole, Breast Neoplasms, 03 medical and health sciences, Breast cancer, breast cancer, adjuvant, SDG 3 - Good Health and Well-being, Internal medicine, Humans, bone health, Aromatase inhibitor, business.industry, endocrine therapy, Bisphosphonate, medicine.disease, osteoporosis, Osteopenia, Zoledronic acid, osteopenia, AROMATASE INHIBITOR, MINERAL DENSITY, business, bone mineral density, Tamoxifen

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0d75c26646b7999037a83fd370e350Test
https://doi.org/10.1002/ijc.32205Test

المؤلفون: Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-De Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Group, TEAM Study Group

المصدر: European Journal of Cancer

مصطلحات موضوعية: Breast cancer, Extended endocrine therapy, Clinical trial, Compliance, Early treatment discontinuation, Adverse events, Survival, Aromatase inhibitor, Tamoxifen

العلاقة: lumc-id: 44393910; https://hdl.handle.net/1887/95506Test

الإتاحة: https://doi.org/10.1016/j.ejca.2018.03.014Test
https://hdl.handle.net/1887/95506Test